Publications by authors named "Daniel M Sullivan"

Claim this Profile
E
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.
Rafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, Maria Silva, Xiaohong Zhao, Daniel M Sullivan

Res Sq· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao, Daniel M Sullivan

Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Joel G Turner, Yan Cui, Alexis A Bauer, Jana L Dawson, Juan A Gomez, Daniel M Sullivan

Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L Cubitt, Joel G Turner, Daniel M Sullivan

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
Rachid Baz, Syeda Mahrukh Hussnain Naqvi, Jae-Hoon Lee, Jason Brayer, Nancy Hillgruber, Daniel M Sullivan

Br J Haematol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer.
Hatem Soliman, Fatema Khambati, Hyo S Han, Roohi Ismail-Khan, Marilyn M Bui, Daniel M Sullivan

Oncotarget· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Gemma Shay, Marilena Tauro, Fulvio Loiodice, Paolo Tortorella, Daniel M Sullivan

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Joel G Turner, Trinayan Kashyap, Jana L Dawson, Juan Gomez, Alexis A Bauer, Daniel M Sullivan

Oncotarget· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
Alberto A Chiappori, Gregory A Otterson, Afshin Dowlati, Anne M Traynor, Leora Horn, Daniel M Sullivan

Oncologist· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Joel G Turner, Jana L Dawson, Steven Grant, Kenneth H Shain, William S Dalton, Daniel M Sullivan

J Hematol Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Rachid C Baz, Thomas G Martin, Hui-Yi Lin, Xiuhua Zhao, Kenneth H Shain, Daniel M Sullivan

Blood· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
Alexandra Pisklakova, Eileen Grigson, Maria Ozerova, Feng Chen, Daniel M Sullivan

Cancer Biol Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of indoximod in patients with advanced malignancies.
Hatem H Soliman, Susan E Minton, Hyo Sook Han, Roohi Ismail-Khan, Anthony Neuger, Daniel M Sullivan

Oncotarget· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Damon R Reed, Leo Mascarenhas, Kathleen Manning, Gregory A Hale, John Goldberg, Daniel M Sullivan

Cancer Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.
Eileen R Grigson, Maria Ozerova, Alexandra Pisklakova, Hao Liu, Daniel M Sullivan

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico.
Caroline B Appleyard, Scott J Antonia, Daniel M Sullivan, Pedro G Santiago-Cardona, William Cáceres

Rev Recent Clin Trials· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Lesley Seymour, Susan Groshen, Gary L Rosner, Daniel M Sullivan, David R Spriggs

Clin Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.
Diana Yu, Elliot Kahen, Christopher L Cubitt, Jeremy McGuire, Jenny Kreahling, Daniel M Sullivan

Sci Rep· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Sabiha Kazim, Mokenge P Malafa, Domenico Coppola, Kazim Husain, Sherma Zibadi, Daniel M Sullivan

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Shivaani Kummar, Amit M Oza, Gini F Fleming, Daniel M Sullivan, David R Gandara

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
Amit Mahipal, Aaron C Denson, Benjamin Djulbegovic, Richard Lush, Ambuj Kumar, Daniel M Sullivan

Cancer Control· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Timothy A Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Daniel M Sullivan

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Hatem H Soliman, Erica Jackson, Tony Neuger, E Claire Dees, R Donald Harvey, Daniel M Sullivan

Oncotarget· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Joel G Turner, Jana Dawson, Christopher L Cubitt, Rachid Baz, Daniel M Sullivan

Semin Cancer Biol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, Adriane M Zernhelt, Daniel M Sullivan

J Hematol Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis